Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRITON-CM phase 3 study of nucresiran in transthyretin amyloid cardiomyopathy
CTR20260982Phase 3Active
- Sponsor
- NA/ 百时益医药研发（北京）有限公司
- Start
- Apr 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of nucresiran in amyloidotic transthyretin cardiomyopathy (ATTR-CM), sponsored by NA/ 百时益医药研发（北京）有限公司. Started Apr 2026; status: active.
02
Drugs
nucresiran
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on CTR20260982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260982.